NCT00516295: Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma |
|
|
| Completed | 2 | 7 | US | topotecan hydrochloride, hycamptamine, Hycamtin, SKF S-104864-A, TOPO, vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF | National Cancer Institute (NCI) | Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | 08/09 | 01/10 | | |
